CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orthocell Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orthocell Ltd
Building 191 Murdoch University
South Street Murdoch
Phone: +61 893602888p:+61 893602888 PERTH, WAS  6150  Australia Ticker: OCCOCC
Business Summary
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board JohnVan Der Wielen 6/1/2023 6/1/2023
Chief Financial Officer NicoleTelford
Chief Scientific Officer Ming HaoZheng
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 209,326,818 (As of 6/30/2024)
Shareholders: 5,006
Stock Exchange: ASX
Fax Number: +61 893602899


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025